论文部分内容阅读
目的研究胃泌素及其受体拮抗剂对原代培养胃癌细胞的作用,探讨胃癌患者非细胞毒内分泌治疗的可行性。方法从新鲜胃癌切除标本中分离胃癌细胞进行体外培养,应用MTT比色分析法和流式细胞仪观察胃泌素及其受体拮抗剂丙谷胺对细胞增殖、周期分布的影响。结果胃泌素可明显促进部分胃癌细胞的增殖,使细胞从G0/G1期向S期和G2/M期转化,与对照组比较有显著差异(P<0.01),丙谷胺可阻断胃泌素的作用。对胃泌素敏感的胃癌原发部位多在胃体部(13/34)和贲门部(15/34),胃窦部较少(6/34);以低分化或未分化腺癌为主(77.1%),多为中晚期。结论胃泌素可促进部分胃癌患者肿瘤细胞的增殖和细胞内DNA合成,以胃体、贲门癌为著,胃泌素受体拮抗剂可望成为胃癌非细胞毒内分泌治疗新途径。
Objective To study the effect of gastrin and its receptor antagonist on primary cultured gastric cancer cells and explore the feasibility of non-cytotoxic endocrine therapy in patients with gastric cancer. Methods Gastric cancer cells were isolated from fresh gastric cancer specimens and cultured in vitro. MTT assay and flow cytometry were used to observe the effect of gastrin and its receptor antagonist proglumide on cell proliferation and cell cycle distribution. Results Gastrin could obviously promote the proliferation of some gastric cancer cells and make the cells transform from G0 / G1 phase to S phase and G2 / M phase, and there was significant difference compared with control group (P <0.01). Promethazine could block gastric The role of the hormone. Gastrin-sensitive gastric cancer more than the main parts of the stomach (13/34) and cardia (15/34), less gastric antrum (6/34); mainly poorly differentiated or undifferentiated adenocarcinoma (77.1%), mostly in the late. Conclusion Gastrin can promote the proliferation of tumor cells and the synthesis of DNA in gastric cancer patients. Gastrin receptor antagonist is expected to become a new way of non-cytotoxic endocrine therapy for gastric cancer.